Home › Research › Digital health tools
The many faces of corticobasal degeneration
Wadia PM, Lang AE.. Parkinsonism & related disorders, 2007-01-01
Topic: Risk, prevention and care in population studies
Corticobasal degeneration (CBD) has characteristic neuropathological features, but is a clinically heterogeneous disorder. It can present with various clinical syndromes. The corticobasal syndrome (CBS) is the best recognized and over the course of the illness may be the most common manifestation. Dementia, progressive non-fluent aphasia, speech apraxia, progressive supranuclear palsy (PSP)-like syndrome and posterior cortical atrophy syndrome are other presentations of CBD. The CBS is not specific for the pathology of CBD. Patients presenting as CBS have CBD as the underlying pathology in about 55% of the cases, PSP pathology in 20%, Pick's disease in 7%, and non tau pathology in the remaining. CBS is a sensitive clinical phenotype for tau pathology. Patients with CBS could potentially be candidates for therapies aiming to modify tau biochemistry.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wadia, P. M., & Lang, A. E. (2007). The many faces of corticobasal degeneration. Parkinsonism & related disorders. https://doi.org/10.1016/s1353-8020(08)70027-0
Vancouver
Wadia PM, Lang AE. The many faces of corticobasal degeneration. Parkinsonism & related disorders. 2007. doi:10.1016/s1353-8020(08)70027-0. PMID: 18267261.
BibTeX
@article{wadia2007-18267261,
author = {Wadia, P. M. and Lang, A. E.},
title = {{The many faces of corticobasal degeneration}},
journal = {Parkinsonism \& related disorders},
year = {2007},
doi = {10.1016/s1353-8020(08)70027-0},
pmid = {18267261},
url = {https://doi.org/10.1016/s1353-8020(08)70027-0}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Dementia, progressive non-fluent aphasia, speech apraxia, progressive supranuclear palsy (PSP)-like syndrome and posterior cortical atrophy syndrome are other presentations of CBD.
- The CBS is not specific for the pathology of CBD.
- Patients presenting as CBS have CBD as the underlying pathology in about 55% of the cases, PSP pathology in 20%, Pick's disease in 7%, and non tau pathology in the remaining.
- CBS is a sensitive clinical phenotype for tau pathology.
- Patients with CBS could potentially be candidates for therapies aiming to modify tau biochemistry.
Why it matters
This review describes the clinical heterogeneity of corticobasal degeneration, noting that the corticobasal syndrome is not specific for its pathology and that patients with this syndrome could potentially be candidates for therapies aiming to modify tau biochemistry. It does not itself test any treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Parkinsonism & related disorders) |
| Journal's citation record | 2 / 4 | Parkinsonism & Related Disorders: journal h-index 155 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2007 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 114 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.4 citations a year over 21 year(s) since 2007 |
| Impact for its field and year | 3 / 6 | Cited 3.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Anthony E. Lang: h-index 168 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Toronto: institution h-index 1,923 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18267261) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Digital health tools
Also in Digital health tools
178 studies in the library are filed under Digital health tools with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Digital health tools hub.